MUC1: An emerging target in cancer treatment and diagnosis.

Qing, Liangliang; Li, Qingchao; Dong, Zhilong

Qing, Liangliang; Li, Qingchao; Dong, Zhilong.

Afiliación

Qing L; Department of Urology, Lanzhou University Second Hospital, Lanzhou, China; Gansu Nephro-Urological Clinical Center, Institute of Urology, Department of Urology, Key Laboratory of Urological Disease of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China.
Li Q; Department of Urology, Lanzhou University Second Hospital, Lanzhou, China; Gansu Nephro-Urological Clinical Center, Institute of Urology, Department of Urology, Key Laboratory of Urological Disease of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China.
Dong Z; Department of Urology, Lanzhou University Second Hospital, Lanzhou, China; Gansu Nephro-Urological Clinical Center, Institute of Urology, Department of Urology, Key Laboratory of Urological Disease of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China. Electronic address: dzl19780829@163.com.

Bull Cancer ; 109(11): 1202-1216, 2022 Nov.

Article en En | MEDLINE | ID: mdl-36184332

Asunto(s)

Mucina-1; Neoplasias; Humanos; Anticuerpos Monoclonales; Vacunas contra el Cáncer; Epítopos/química; Epítopos/metabolismo; Glicosilación; Mucinas; Neoplasias/diagnóstico; Neoplasias/tratamiento farmacológico

Palabras clave

Cancer; Diagnosis; MUC1; Molecular mechanism; Prognosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mucina-1 / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Bull Cancer Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google